Abstract

Ionis Pharmaceuticals will report second-quarter 2026 results Pre-MKt on July 29, 2026; this preview summarizes consensus forecasts for revenue, margins, net income, and EPS, reviews last quarter’s performance, and outlines the key swing factors that could drive the print and near-term stock reaction.

Market Forecast

Based on current-quarter forecasts, Ionis Pharmaceuticals’ revenue is projected at 189.14 million US dollars, implying a year-over-year decline of 35.92%, with EBIT estimated at a loss of 182.36 million US dollars and EPS at a loss of 1.09; year-over-year forecast growth rates translate to -306.50% for EBIT and -154.18% for EPS. Margin consensus points to pressure near term; management’s gross margin and net margin guidance for the current quarter are not disclosed in the dataset, though last quarter’s gross margin and net margin provide the latest baseline for comparison. The main business is expected to be driven by collaboration-related research and development revenue timing and commercial product contributions; milestone recognition remains uneven across periods. The most promising segment remains commercial revenue, which is expected to benefit from continued uptake of marketed products; prior quarter commercial revenue was 107.81 million US dollars, while research and development revenue was 138.28 million US dollars.

Last Quarter Review

Ionis Pharmaceuticals’ last reported quarter delivered revenue of 246.09 million US dollars, a gross profit margin of 13.38%, GAAP net loss attributable to the parent company of 92.53 million US dollars, a net margin of -37.60%, and adjusted EPS of -0.56, with year-over-year adjusted EPS growth of 39.79% and revenue growth of 86.43%; quarter-on-quarter net result improved with a 59.66% change. A key highlight was substantial top-line outperformance versus prior expectations, with EBIT at -117.42 million US dollars improving versus estimates and adjusted EPS beating by 0.35. Main business highlights showed revenue composition led by research and development collaborations at 138.28 million US dollars and commercial revenue at 107.81 million US dollars; year-over-year growth by segment was not disclosed in the dataset.

Current Quarter Outlook

Main commercial engine

Commercial revenue remains a focal point for this quarter. The stock will likely be sensitive to updated trends in prescription demand, refill dynamics, and any commentary on payer coverage and access. Any acceleration in commercial uptake relative to last quarter’s 107.81 million US dollars could partially offset timing variability in collaboration revenue, supporting revenue quality and visibility. Conversely, if the growth cadence softens, investors may extrapolate a slower trajectory into the back half, putting pressure on revenue multiple assumptions and compounding EBIT loss expectations already reflected in the current forecast.

Collaboration and R&D revenue cadence

Research-and-development collaboration revenue can be lumpy due to milestone timing, partner opt-ins, and program advancement gates. The forecasted revenue step-down to 189.14 million US dollars for the current quarter embeds lower milestone recognition compared with the prior quarter’s 246.09 million US dollars. If management confirms additional milestones or near-term catalysts, the revenue bridge for the remainder of the year could firm up, easing concerns around the projected year-over-year decline of 35.92%. If milestones slip into later quarters, the gap to full-year aspirations may widen, and investors will scrutinize operating expense discipline to contain the EBIT loss, which is forecast at -182.36 million US dollars.

Operating leverage and margin trajectory

With the last quarter’s gross margin at 13.38% and net margin at -37.60%, the key debate is whether mix shift toward recurring commercial sales can expand gross margin while operating expense growth moderates. The projected EPS loss of 1.09 and deeper EBIT loss suggest limited near-term operating leverage absent stronger revenue recognition. Any commentary on cost control, clinical prioritization, or phasing of spend across late-stage programs could shift expectations on the path to profitability. Clarity around inventory, COGS normalization, and partner cost sharing would also influence gross margin trajectory for the second half.

Pipeline and regulatory catalysts

Share price reaction often hinges on pipeline updates that can overshadow quarterly financials. Investors will look for visibility into upcoming clinical readouts, regulatory filings, or launch preparations that could reset revenue expectations beyond the quarter. Confirmation of timelines and partner engagement can reduce uncertainty around collaboration revenue timing and future commercial scale. If management signals that key milestones are tracking into the near to medium term, it could mitigate the effect of a softer quarterly revenue print.

Cash runway and capital planning

Although not explicitly detailed in the dataset, the forecasted EBIT and EPS losses keep attention on liquidity and runway. Commentary about cash burn, potential for non-dilutive funding from partnerships, and disciplined allocation across programs can alleviate concerns about financing needs. Any shift in the balance between internally funded pipeline work and partner-supported development could reduce volatility in quarterly losses.

Analyst Opinions

The prevailing institutional stance appears cautious given the forecasted year-over-year revenue decline of 35.92% and deeper projected losses on EBIT and EPS. Several analysts emphasize the uncertainty around milestone timing and the need for sustained commercial momentum to counterbalance collaboration variability. The cautious view outnumbers bullish takes in the recent commentary set, citing the risk that revenue recognition could be back-half weighted, leaving the current quarter vulnerable to downside versus consensus if milestones slip. Noted research desks point to near-term volatility tied to clinical and regulatory catalysts that may be more consequential for valuation than a single quarter’s print. They also highlight that last quarter’s beat on both revenue and EPS creates a tougher sequential comparison. The majority opinion stresses that proof points on commercial trajectory and improved visibility on milestones are required to re-rate expectations higher. Consequently, the consensus into July 29, 2026, leans toward a guarded stance on the quarter, with attention centered on updates that could improve visibility for the remainder of the year.